Brain Advance Access published online on May 21, 2003
Brain, doi:10.1093/brain/awg172
© 2003 by Guarantors of Brain
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review article
1 Genetic-Epidemiologic Unit, Departments of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands
* Corresponding author. E-mail: m.dekker{at}erasmusmc.nl.
Received 8 February 2003
; revised 17 March 2003
; accepted 20 March 2003
The role of genetics in the pathogenesis of Parkinson's disease has been subject to debate for decades. In recent years, the discovery of five genes and several more loci has provided important insight into its molecular aetiology. Some Parkinson's disease genes possibly cause Parkinson's disease by protein aggregation. The presence of Lewy bodies in carriers of mutations in one gene and their absence in carriers of another, however, still point towards a complex pathogenic network, with Parkinson's disease as a common clinical end point. The recent identification of the fourth and fifth Parkinson's disease genes suggests multiple pathways--an impaired oxidative stress defence for mutations in DJ-1, and a defect in another signalling pathway for mutations in NR4A2. Despite knowledge of genetics in familial Parkinson's disease, our knowledge of the common, late-onset form of Parkinson's disease remains limited. In non-familial Parkinson's disease, genes and environment probably interact to give rise to the disease. We review advances in the genetics of Parkinson's disease, focusing on the monogenic forms and their clinical and population-genetic consequences.
Keywords: Parkinson's disease; genetics; review; population risk
Parkinson's disease: piecing together a genetic jigsaw
2 Genetic-Epidemiologic Unit, Departments of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands; Department of Neurological Sciences, La Sapienza University, Rome, Italy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. W. Olanow, M. B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, L. N. Clark, E. D. Louis, H. Mejia-Santana, J. Harris, L. J. Cote, C. Waters, H. Andrews, B. Ford, S. Frucht, et al. Risk of Parkinson Disease in Carriers of Parkin Mutations: Estimation Using the Kin-Cohort Method Arch Neurol, April 1, 2008; 65(4): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Stichel, X.-R. Zhu, V. Bader, B. Linnartz, S. Schmidt, and H. Lubbert Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage Hum. Mol. Genet., October 15, 2007; 16(20): 2377 - 2393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jiang, Q. Jiang, W. Liu, and J. Feng Parkin Suppresses the Expression of Monoamine Oxidases J. Biol. Chem., March 31, 2006; 281(13): 8591 - 8599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Khan, S. Jain, J. M. Lynch, N. Pavese, P. Abou-Sleiman, J. L. Holton, D. G. Healy, W. P. Gilks, M. G. Sweeney, M. Ganguly, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data Brain, December 1, 2005; 128(12): 2786 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Allard, P. R. Burkhard, P. Lescuyer, J. A. Burgess, N. Walter, D. F. Hochstrasser, and J.-C. Sanchez PARK7 and Nucleoside Diphosphate Kinase A as Plasma Markers for the Early Diagnosis of Stroke Clin. Chem., November 1, 2005; 51(11): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Skipper, H. Shen, E. Chua, C. Bonnard, P. Kolatkar, L.C.S. Tan, R. D. Jamora, K. Puvan, K. Y. Puong, Y. Zhao, et al. Analysis of LRRK2 functional domains in nondominant Parkinson disease Neurology, October 25, 2005; 65(8): 1319 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Callio, T. D. Oury, and C. T. Chu Manganese Superoxide Dismutase Protects against 6-Hydroxydopamine Injury in Mouse Brains J. Biol. Chem., May 6, 2005; 280(18): 18536 - 18542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yang, Q. Jiang, J. Zhao, Y. Ren, M. D. Sutton, and J. Feng Parkin Stabilizes Microtubules through Strong Binding Mediated by Three Independent Domains J. Biol. Chem., April 29, 2005; 280(17): 17154 - 17162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jiang, Q. Jiang, and J. Feng Parkin Increases Dopamine Uptake by Enhancing the Cell Surface Expression of Dopamine Transporter J. Biol. Chem., December 24, 2004; 279(52): 54380 - 54386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jiang, Y. Ren, J. Zhao, and J. Feng Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis Hum. Mol. Genet., August 15, 2004; 13(16): 1745 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Michell, S. J. G. Lewis, T. Foltynie, and R. A. Barker Biomarkers and Parkinson's disease Brain, August 1, 2004; 127(8): 1693 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wirdefeldt, M. Gatz, M. Schalling, and N. L. Pedersen No evidence for heritability of Parkinson disease in Swedish twins Neurology, July 27, 2004; 63(2): 305 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kuhlenbaumer, P. Ludemann, A. Schirmacher, E. De Vriendt, G. Hunermund, P. Young, M. Hund-Georgiadis, G. Schuierer, H. Moller, E. B. Ringelstein, et al. Autosomal dominant striatal degeneration (ADSD): Clinical description and mapping to 5q13-5q14 Neurology, June 22, 2004; 62(12): 2203 - 2208. [Abstract] [Full Text] [PDF]
|
|